CN104910159A - 纯化的吡咯并喹啉基-吡咯烷-2,5-二酮组合物和用于制备且使用其的方法 - Google Patents

纯化的吡咯并喹啉基-吡咯烷-2,5-二酮组合物和用于制备且使用其的方法 Download PDF

Info

Publication number
CN104910159A
CN104910159A CN201510243421.1A CN201510243421A CN104910159A CN 104910159 A CN104910159 A CN 104910159A CN 201510243421 A CN201510243421 A CN 201510243421A CN 104910159 A CN104910159 A CN 104910159A
Authority
CN
China
Prior art keywords
pyrrolo
dihydro
trans
indol
quinoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510243421.1A
Other languages
English (en)
Chinese (zh)
Inventor
D.P.里德
N.R.巴恩斯
J.C.凯恩
C.A.李
J.陈
M.P.雷蒙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arqule Inc
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc filed Critical Arqule Inc
Publication of CN104910159A publication Critical patent/CN104910159A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201510243421.1A 2009-12-23 2010-12-21 纯化的吡咯并喹啉基-吡咯烷-2,5-二酮组合物和用于制备且使用其的方法 Pending CN104910159A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28956309P 2009-12-23 2009-12-23
US61/289563 2009-12-23
CN201080064457.9A CN102834097B (zh) 2009-12-23 2010-12-21 纯化的吡咯并喹啉基-吡咯烷-2,5-二酮组合物和用于制备且使用其的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201080064457.9A Division CN102834097B (zh) 2009-12-23 2010-12-21 纯化的吡咯并喹啉基-吡咯烷-2,5-二酮组合物和用于制备且使用其的方法

Publications (1)

Publication Number Publication Date
CN104910159A true CN104910159A (zh) 2015-09-16

Family

ID=44188284

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201510243421.1A Pending CN104910159A (zh) 2009-12-23 2010-12-21 纯化的吡咯并喹啉基-吡咯烷-2,5-二酮组合物和用于制备且使用其的方法
CN201080064457.9A Active CN102834097B (zh) 2009-12-23 2010-12-21 纯化的吡咯并喹啉基-吡咯烷-2,5-二酮组合物和用于制备且使用其的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201080064457.9A Active CN102834097B (zh) 2009-12-23 2010-12-21 纯化的吡咯并喹啉基-吡咯烷-2,5-二酮组合物和用于制备且使用其的方法

Country Status (19)

Country Link
US (3) US8552192B2 (cg-RX-API-DMAC7.html)
EP (2) EP2515904A4 (cg-RX-API-DMAC7.html)
JP (2) JP2013515737A (cg-RX-API-DMAC7.html)
KR (2) KR101669707B1 (cg-RX-API-DMAC7.html)
CN (2) CN104910159A (cg-RX-API-DMAC7.html)
AU (2) AU2010336533B9 (cg-RX-API-DMAC7.html)
BR (1) BR112012015656A2 (cg-RX-API-DMAC7.html)
CA (1) CA2785503A1 (cg-RX-API-DMAC7.html)
CO (1) CO6561823A2 (cg-RX-API-DMAC7.html)
HK (1) HK1215025A1 (cg-RX-API-DMAC7.html)
MX (1) MX2012007259A (cg-RX-API-DMAC7.html)
MY (2) MY169232A (cg-RX-API-DMAC7.html)
NZ (2) NZ600800A (cg-RX-API-DMAC7.html)
PH (2) PH12012501293A1 (cg-RX-API-DMAC7.html)
RU (1) RU2556205C2 (cg-RX-API-DMAC7.html)
SG (1) SG181927A1 (cg-RX-API-DMAC7.html)
TW (3) TWI557125B (cg-RX-API-DMAC7.html)
WO (1) WO2011079142A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201204759B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS51826B (sr) * 2005-02-09 2012-02-29 Arqule Inc. Maleimid derivati, farmaceutske kompozicije i postupak lečenja kancera
JP2013515737A (ja) * 2009-12-23 2013-05-09 アークル インコーポレイテッド 精製されたピロロキノリニル−ピロリジン−2,5−ジオン組成物ならびにその調製方法および使用方法
KR20140146036A (ko) * 2011-07-07 2014-12-24 아르퀼 인코포레이티드 피롤로퀴놀리닐-피롤리딘-2,5-디온 제제 및 이의 제조 및 사용 방법
EP2841069A4 (en) * 2012-04-23 2015-09-02 Arqule Inc HIGHLY PYRROLOCHINOLINYL-PYRROL-2,5-DION AND PYRROLOCHINOLINYL-PYRROLIDIN-2,5-DION AND METHOD FOR THE PRODUCTION THEREOF
EP3021849B1 (en) * 2013-07-16 2019-10-09 Dr. Reddy's Laboratories Ltd. Novel crystalline forms of pemetrexed tromethamine salts
KR20250070131A (ko) * 2017-08-11 2025-05-20 액투에이트 테라퓨틱스 인크. 3-(5-플루오로벤조푸란-3-일)-4-(5-메틸-5H-[1,3]디옥솔로[4,5-f]인돌-7-일)피롤-2,5-디온의고체 형태
CN110806454A (zh) * 2018-08-06 2020-02-18 江苏正大清江制药有限公司 一种盐酸吉西他滨中手性异构体的检测方法
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4319740A4 (en) * 2021-04-07 2025-03-19 Crystalys Therapeutics, Inc. URAT1 INHIBITOR, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE4128015A1 (de) * 1991-08-23 1993-02-25 Kali Chemie Pharma Gmbh 1,7-anellierte 2-(piperazinoalkyl)indol-derivate sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindugnen enthaltende arzneimittel
US5760237A (en) * 1995-08-25 1998-06-02 California Institute Of Technology Synthesis of l-azatyrosine using pseudoephedrine as a chiral auxiliary
WO2001044247A2 (en) * 1999-12-16 2001-06-21 Eli Lilly And Company Agents and methods for the treatment of proliferative diseases
ATE315017T1 (de) * 2002-07-31 2006-02-15 Firmenich & Cie Verfahren zur racematspaltung einer sclareolid- vorstufe
EP1786772A1 (en) * 2004-09-10 2007-05-23 Wyeth a Corporation of the State of Delaware Process for the scalable synthesis of 1, 3, 4, 9-tetrahydropyranoý3, 4-b¨-indole derivatives
RS51826B (sr) * 2005-02-09 2012-02-29 Arqule Inc. Maleimid derivati, farmaceutske kompozicije i postupak lečenja kancera
US20070185346A1 (en) * 2006-02-03 2007-08-09 Vaidya Niteen A Kit for automated resolving agent selection and method thereof
CA2690799C (en) 2007-06-22 2015-06-16 Arqule, Inc. Pyrrolidinone, pyrrolidine-2,5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer
CA2690782C (en) * 2007-06-22 2016-02-02 Arqule, Inc. Compositions and methods for treatment of cancer
JP2013515737A (ja) * 2009-12-23 2013-05-09 アークル インコーポレイテッド 精製されたピロロキノリニル−ピロリジン−2,5−ジオン組成物ならびにその調製方法および使用方法
EP2841069A4 (en) * 2012-04-23 2015-09-02 Arqule Inc HIGHLY PYRROLOCHINOLINYL-PYRROL-2,5-DION AND PYRROLOCHINOLINYL-PYRROLIDIN-2,5-DION AND METHOD FOR THE PRODUCTION THEREOF

Also Published As

Publication number Publication date
PH12012501293A1 (en) 2013-01-07
AU2015243015B2 (en) 2017-02-02
KR20160121602A (ko) 2016-10-19
AU2010336533B9 (en) 2015-10-08
RU2556205C2 (ru) 2015-07-10
KR101669707B1 (ko) 2016-10-27
NZ628087A (en) 2016-02-26
KR20120113760A (ko) 2012-10-15
AU2010336533A1 (en) 2012-07-12
WO2011079142A3 (en) 2011-11-24
WO2011079142A2 (en) 2011-06-30
NZ600800A (en) 2014-10-31
US8871933B2 (en) 2014-10-28
EP2515904A4 (en) 2013-07-03
CA2785503A1 (en) 2011-06-30
RU2012131344A (ru) 2014-01-27
CN102834097B (zh) 2015-06-17
US20160024076A1 (en) 2016-01-28
JP2013515737A (ja) 2013-05-09
AU2015243015A1 (en) 2015-11-05
ZA201204759B (en) 2014-03-26
US20110160242A1 (en) 2011-06-30
TW201141865A (en) 2011-12-01
US20140031551A1 (en) 2014-01-30
TWI557125B (zh) 2016-11-11
CO6561823A2 (es) 2012-11-15
MY169232A (en) 2019-03-19
TW201542546A (zh) 2015-11-16
CN102834097A (zh) 2012-12-19
PH12014500310A1 (en) 2015-09-28
HK1215025A1 (zh) 2016-08-12
US8552192B2 (en) 2013-10-08
EP2515904A2 (en) 2012-10-31
AU2010336533B2 (en) 2015-09-10
EP3081567A3 (en) 2016-11-16
SG181927A1 (en) 2012-07-30
US9499540B2 (en) 2016-11-22
MY156701A (en) 2016-03-15
EP3081567A2 (en) 2016-10-19
TW201643163A (zh) 2016-12-16
MX2012007259A (es) 2015-05-15
TWI506026B (zh) 2015-11-01
BR112012015656A2 (pt) 2016-05-10
JP2016041712A (ja) 2016-03-31

Similar Documents

Publication Publication Date Title
CN102834097B (zh) 纯化的吡咯并喹啉基-吡咯烷-2,5-二酮组合物和用于制备且使用其的方法
CN103282365B (zh) 结晶的(8S,9R)‑5‑氟‑8‑(4‑氟苯基)‑9‑(1‑甲基‑1H‑1,2,4‑三唑‑5‑基)‑8,9‑二氢‑2H‑吡啶并[4,3,2‑de]酞嗪‑3(7H)‑酮甲苯磺酸盐
CN107074769B (zh) 用于治疗增生性病症的组合物和方法
EP3350180B1 (en) 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2-one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer
AU2015257456B2 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
CN101133055A (zh) 用于治疗癌症的meleimide衍生物、药物组合物以及方法
EP4353724A1 (en) Compound as cdk kinase inhibitor and use thereof
JP2021504332A (ja) ピラゾロピリジノン化合物
US8343977B2 (en) Substituted triazolo-pyrimidine compounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1215025

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150916

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1215025

Country of ref document: HK